Home » Newsletters » BioWorld Science

BioWorld Science

May 29, 2008

View Archived Issues

Responses seen with WT1 peptide vaccine in glioblastoma multiforme patients

Amitiza hits U.S. market following recent presentations of phase III clinical trials

Migenix refocuses its programs

Age-related NADH oxidase as a potential target for skin aging therapy

COMT inhibition as a potential therapeutic strategy for schizophrenia

Phase III results reveal efficacy of ospemifene for vulvovaginal atrophy symptoms

ABT-089 improves the symptoms of attention deficit hyperactivity disorder in adults

BiPar Sciences commences phase II BSI-201 study in uterine carcinosarcoma

Juvaris initiates phase I JVRS-100 adjuvanted seasonal influenza vaccine trial

Provectus initiates phase II PH-10 trial in atopic dermatitis

Santaris begins human clinical testing of HCV drug candidate SPC-3649

Sonus and OncoGenex Technologies merge

NicOx completes enrollment in phase III clinical trial of naproxcinod in osteoarthritis

Isis to receive USD 4.6 million from Alnylam resulting from transaction with Takeda

New treatments for dental diseases reported in recent University of Tokyo patent

Recent Chugai patent describes novel antibody for hemophilia

Pluristem reports results from animal trials of PLX cells for IBD

FDA accepts for filing Watson's NDA for oxybutynin chloride topical gel for overactive bladder

Novel analgesic agents imparted in recent patent literature

Ablynx initiates phase Ib study of antithrombotic ALX-0081 for von Willebrand factor

NeuroSearch issues new shares to finance milestone payment related to ACR-16

NanoViricides enters nondisclosure agreements for nanoviricide drug candidate in EKC

Roche completes acquisition of Piramed

Rolling NDA commences for Lucassin in hepatorenal syndrome type 1

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.